Estimating the impact of decreasing vaccination response times for outbreaks in low- and middle-income countries

Dominic Delport, MSc[1,2]; Alina M. Muellenmeister, MSc[1]; Jane Greig, PhD[1]; Romesh Gerald Abeysuriya, PhD[1,2,*]; Nick Scott, PhD[1,2,*]

1 Burnet Institute, Melbourne, VIC 3004, Australia

2 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia

* Equal senior author

Corresponding author: Dominic Delport, dominic.delport@burnet.edu.au, 85 Commercial Rd, Melbourne, VIC 3004, Australia

Background

Immunisation is an effective tool for responding to disease outbreaks, but in low- and middle-income countries (LMICs) accessing vaccine stockpiles can be slowed by logistical challenges. The 7-1-7 outbreak timeliness targets propose that outbreaks be detected within seven days; notification occur within one day; and responses be started within another seven days. For outbreaks of measles, cholera, yellow fever, and meningococcal meningitis, we aim to estimate the impact of initiating outbreak response immunisation (ORI) programs within 15 days of outbreak emergence, relative to the mean ORI response time for each disease since 2000.

Methods

Using calibrated agent-based models for the four diseases, a status-quo and series of 'Faster response' scenarios were compared for each disease, with a 15-day response time (7-1-7) as the minimum.

Findings

A 15-day ORI response could avert: 80% of cases from cholera outbreaks relative to a response time of 105 days; 35% of cases from meningococcal meningitis outbreaks relative to a response time of 75 days; 0–35% of cases from yellow fever outbreaks relative to a response time of 105 days (depending on routine vaccine coverage and environmental suitability); and 0–55% of cases from measles outbreaks relative to a response time of 120 days (depending on routine vaccine coverage).

Interpretation

Improvements made to ORI response time while aiming for 7-1-7 could reduce disease burden and decrease the risk of large outbreaks of vaccine-preventable diseases in LMICs. Efforts to improve response time should be prioritized to higher risk settings.

Funding source

Nothing to disclose.

Acknowledgements

The authors thank Gabrielle MacKechnie, Dr Stefanie Vaccher, Dr Todi Mengistu, and Dr Dan Hogan for their previous contributions to the outbreak dataset and models used in this analysis.

Research in context

What is already known on this topic

We searched PubMed and Google Scholar on November 18, 2024, without date limits, using the search terms "((((outbreak response) AND (impact) AND (response time OR delay)) AND (model)) AND (countries)) AND (mortality OR morbidity)". Studies were included if they used modelling approaches to estimate the health impact of varying the response time for reactive vaccination for at least one pathogen. We found there to be a lack of work using mathematical models to investigate the relationship between outbreak response time and vaccine impact. Of 302 results from PubMed, three studies met the inclusion criteria and in the first 50 pages (500 results) of Google Scholar, two studies met the criteria. A further eight studies were found incidentally over the course of the literature review. Of these 13 studies, three focused on measles, three on meningococcal meningitis, and one on each of cholera, Ebola, poliovirus, MERS-CoV, SARS-CoV-2, yellow fever, and a generalised SEIR model. No study considered multiple diseases, and none were considering the impact of achieving the 7-1-7 goal.

What this study adds

This study contributes to the existing literature by estimating the impacts of achieving the 7-1-7 targets for outbreaks of four high burden vaccine preventable diseases (measles, cholera, meningococcal meningitis, and yellow fever) in low- and middle-income countries, using agent-based models calibrated to historical outbreak data. We use agent-based models to capture the stochastic effects present in the early stages of an outbreak, and report the reductions in cases, deaths, and disability adjusted life years achieved by achieving 7-1-7 relative to the mean historical response time for each disease. We also investigate the incremental impacts of improvements to response time in steps down to a minimum of 15 days (7-1-7).

How this study might affect research, practice or policy

Outbreaks of vaccine preventable diseases still occur frequently in low- and middle-income countries because routine immunization programs are not available or there are gaps in coverage. When outbreaks do occur, vaccination responses can take weeks to months to begin. This study shows that if outbreak response immunization can be initiated within 15 days, then much more of the health burden can be averted relative to what is typically prevented. Furthermore, we found that incremental improvements in outbreak response immunization times can still have impacts reducing cases, even if a 15-day target is not met, and that the impacts of improvement are heterogeneous with greater benefits in higher risk settings. This serves as motivation for the implementation of outbreak response timeliness targets like 7-1-7, and suggests that nuanced and context-specific approaches to measuring and improving outbreak response timeliness may be an effective way to prioritize resources.

Introduction

The COVID-19 pandemic and 2013-2016 West African Ebola epidemic are two stark, recent examples of how vital it is to have effective systems of detection, notification, and response to combat disease outbreaks, and how disruptive and devastating they can become if the systems are unprepared. The 7-1-7 targets developed by Resolve to Save Lives are gaining traction as metrics for assessing a country's outbreak readiness; they propose that outbreaks be detected within seven days; notification occur within one day; and key early response actions be started within another seven days[1]. Relatively few countries have adopted these metrics yet, and of 41 public health events assessed across five low- and middle-income countries (LMICs) between 2018–2022, only 27% fully satisfied the 7-1-7 targets[2]. Ideally, use of the 7-1-7 targets with bottleneck and enabler identification can make every outbreak an opportunity for public health system performance improvement, and as a tool for clear communication of improvement to stakeholders[2].

Outbreaks of vaccine-preventable diseases (VPDs) frequently occur in LMICs, often requiring outbreak response immunisation (ORI) programs and other containment interventions[3-5]. Immunisation is a highly effective tool available for prevention of and response to disease outbreaks[6-8]. However, despite awareness, monitoring, and accessible stockpiles of vaccines[9], it can still take weeks or months for vaccines to be delivered once disease outbreaks are detected[3, 8, 10, 11]. Governments and organisations which fund outbreak response programs seek metrics by which to assess the timeliness of these responses, as a measure of success and to identify areas for improvement, but in LMICs the lack of consistent reporting makes benchmarking and target setting challenging[2, 10, 12-14]. It is expected that non-pharmaceutical interventions (e.g., contact tracing or public health messaging) can typically be initiated quickly in outbreak contexts by utilising existing workforces and systems, but accessing vaccine stockpiles can be slowed by logistical challenges (e.g., physical distance or cold-chain constraints). Therefore, there is clear scope for improvement in a critical element of outbreak response, and mathematical models can be used to quantify the impact of ORI timeliness for policy makers.

Previous modelling work found that for outbreaks of four diseases — measles, meningococcal meningitis, yellow fever, and cholera — the time between detection and immunisation response had considerable impact on the proportion of disease burden averted by ORI. Faster immunisation responses (typically around one month) consistently prevented a higher proportion of disease burden than outbreaks with slower responses (typically three to six months)[8]. Despite this, the typical immunisation response time for outbreaks of these diseases in LMICs is two to four months, with the Immunization Agenda 2030 scorecard indicating that less than 30% of outbreaks had a timely detection and response between 2021-2023[15]. To our knowledge, there are a limited number of publications investigating the relationship between ORI timeliness and disease burden for outbreaks of VPDs using mathematical modelling techniques[16-26], and none which estimate the impacts of achieving 7-1-7 targets.

In this study, we estimate the impact of improving ORI response times for outbreaks of measles, cholera, yellow fever, and meningococcal meningitis down to a minimum ORI response time of 15 days to assess the incremental benefits of ORI timeliness gains in the context of 7-1-7. For the purposes of this analysis, we considered 'ORI response time' to be

the time between an outbreak beginning and the initiation of an immunisation response delivered to the population at-risk.

Methods

Models

We used previously developed agent-based models for measles, cholera, meningococcal meningitis (serogroups C, W, X, Y), and yellow fever[8], which were built using the *Starsim* toolbox[27]. The population characteristics (age and household size distributions) of the agents in each model were representative of the populations where outbreaks occurred in our calibration dataset[8].

Settings

Each model was calibrated to a set of historical outbreaks, such that the range of outbreak sizes and durations observed in the dataset were reproduced by model simulations, when controlling for epidemiological and ORI response parameters such as response time, daily vaccination rate, routine vaccine coverage, the mosquito-to-human transmission modifier, or the asymptomatic carriage prevalence[8]. The transmission modifier parameter was used to capture the impact of temperature and rainfall on mosquito population size and biting behaviours on yellow fever transmission in outbreak settings. Asymptomatic carriage prevalence was a parameter used to modify the initial growth rate of an outbreak as an epidemic season begins in meningitis outbreak settings. By simulating outbreaks over a range of values for these parameters we aimed to explore the impact of ORI response time for different 'setting archetypes' in which transmission was expected to be relatively higher or lower for each disease.

The calibrated disease models were used to run simulations of future outbreaks in a generalised population, with ORI response parameters based on the mean values from the outbreak dataset (unless varied as a part of a scenario analysis). Each model simulated a population of 50,000 agents, and each scenario analysed comprised 1000 stochastic simulations. Supplement 1 contains an explanation of the analysis structure and the methods which were consistent across the four models, and descriptions of the model parameters and calibrations are available in Supplements 2–5.

Data

We used a previously formulated dataset which contains relevant epidemiological and programmatic response data for 51 measles, 40 cholera, 24 meningococcal meningitis, and 88 yellow fever outbreaks between 2000–2023 to calibrate our disease models[8]. The mean ORI response time and daily vaccination rate from the set of outbreaks from each disease were used to inform Baseline scenario parameters.

Scenarios

To estimate the impact of ORI response time on outbreak outcomes for each disease we ran two main scenarios and two sensitivity analyses:

- *Baseline*; response time and daily vaccination rate were based on the mean value from the outbreak dataset for each disease, and ORI was assumed to achieve 75% coverage

in the target population (except for measles, which we assumed achieved 100% coverage);

- *Faster response time*; the ORI response time was varied between 15 days and the Baseline response time in steps of 15 days;
- *Alternate coverage (sensitivity analysis)*; the ORI coverage achieved was increased to 100% (except for measles, which was varied between 60% and 90% coverage in steps of 10%) in the target population. For meningococcal meningitis we also ran an additional sub-scenario with broadened age-eligibility and 75% coverage;
- *Alternate vaccination rate (sensitivity analysis)*; the daily vaccination rate was varied to produce either a one-day campaign or a one-month campaign for each disease.

Table 1 describes the parameter values used and their sources for each disease, and Supplements 2-5 contain details on the disease-specific scenarios.

Table 1: Parameter values used for each scenario analysed for measles, cholera, meningococcal meningitis, and yellow fever.

	Response time (days)		**Achieved coverage**		**Vaccination rate (vaccines/day)**	
Disease	**Baseline**	**Faster response times**	**Baseline**	**Alternate coverage**	**Baseline**	**Alternate vaccination rate**
Measles	120	15–105	100%	60–90%	4360	47,812**; or 1300^^
Cholera	105	15–90	75%	100%	5100	48,997**; or 1300^^
Meningococcal meningitis	75	15–60	75%*	100%*; or 75%^	4300	33,153**; or 800^^
Yellow fever	105	15–90	75%	100%	6560	48,544**; or 1300^^

***** targeting ages 1-29 years; ^ targeting ages 1+ years; ** vaccinating the eligible population in one day; ^^ vaccinating the eligible population in one month

Results



Figure 1: Area plots representing the proportion of outbreak simulations which exceed certain case thresholds as a function of outbreak response immunisation (ORI) response time, for different diseases (rows) and for worst case (left column) and best case (right column) setting archetypes considered. For each panel, the righthand stacked bar represents the distribution of outbreak sizes if no outbreak response immunisation is delivered, and the dashed line represents a 10% threshold for visualization. Panels a) and b) are meningococcal meningitis for settings with 10% and 0·25% initial meningococcal meningitis carriage prevalence, respectively. Panel c) is for cholera (only one setting archetype considered). Panels d) and e) are measles for settings with 50% and 100% routine measles vaccine coverage. Panels f) and g) are yellow fever for settings with 40% and 80% routine yellow fever vaccine coverage (BC) and with a mosquito-human transmission modifier of 1·5 and 0·5, respectively.

Across the four diseases, improvements to ORI response times reduced the proportion of simulations exceeding different outbreak size thresholds in higher risk setting archetypes (i.e., those with lower routine vaccine coverage, higher initial prevalence, or higher transmission modifiers) (Figure 1, left column). This behaviour was not observed (or the relationship was weaker) in the lower risk settings (Figure 1, right column). Additional examples of these figures for different setting archetypes are in Supplements 2, 4, and 5, however those in

Figure 1 were chosen as the 'worst' and 'best' archetypes for each disease (except cholera) which show the highest and lowest overall risks for large outbreaks.

Meningococcal meningitis

The expected size of the meningococcal meningitis outbreaks was strongly dependent on the initial carriage prevalence (Figure S4, Figure S5 in Supplement 2). When the initial prevalence was low outbreaks tended to be quite small and ORI response times had minimal impact on expected outbreak size. However, when the initial prevalence was high the expected outbreak size was larger, and response time had a greater impact on the proportion of simulations which exceeded different case thresholds (Figure 1 and Figure S6 in Supplement 2).

While the ORI response time was more critical for absolute numbers of cases in settings with higher initial prevalence, the relative impact of a faster ORI response time was consistent across the choice of initial prevalence (Figure 2). For example, a 15-day response time was estimated to avert ~35% of the case burden compared to the mean historical response time (75 days) between 2011-2022 regardless of initial prevalence. Similarly, a 30-day response time averted ~25% of the cases, a 45-day response averted ~15%, and a 60-day response averted ~7% (Table S3 in Supplement 2).



Figure 2: Proportional reduction in the mean cumulative cases and deaths for the set of meningococcal meningitis outbreaks with ORI response times of 15, 30, 45, and 60 days relative to the set of outbreaks with a response time of 75 days, estimated using bootstrap resampling. Proportional impacts are grouped vertically by initial asymptomatic carriage prevalence, and the values stated at the bottom of each column are the mean cumulative cases or deaths produced by outbreaks which received ORI after 75 days, i.e., the value serving as the denominator for the proportional reduction estimate.

Cholera

The expected size of the cholera outbreaks was strongly impacted by the ORI response time (Figure S9 in Supplement 3), and the proportion of simulations exceeding certain case thresholds also increased with ORI response time (Figure 1 and Figure S10 in Supplement 3). For example, slower response times noticeably increased the proportion of simulations which exceeded 400 or 500 cumulative cases. When comparing outcomes with faster ORI response times to outcomes with the mean historical response time (105 days) between 2015-2023, a 15-day response time was estimated to avert an additional ~80% of the cases. Similarly, a 30, 45, 60, 75, or 90-day response averted an additional ~70%, ~55%, ~40%, ~30%, or ~25% of the cases, respectively (Figure 3 and Table S5 in Supplement 3).



Figure 3: Proportional reduction in the mean cumulative cases and deaths for the set of outbreaks with response times of 15, 30, 45, 60, 75 and 90 days relative to the set of outbreaks with a response time of 105 days, estimated using bootstrap resampling. The values stated at the bottom of the column are the mean cumulative cases or deaths produced by outbreaks which received ORI after 105 days, i.e., the value serving as the denominator for the proportional reduction estimate.

Measles

The expected size of the measles outbreaks was strongly dependent on the routine vaccine coverage (Figure S13, Figure S14 in Supplement 4), and the proportion of simulations exceeding certain high case thresholds decreased with routine coverage and increased with ORI response time (Figure 1 and Figure S15 in Supplement 4). When the routine vaccine coverage was high (i.e., in a low-risk setting archetype), outbreaks tended to be quite small, even with longer ORI response times. However, in high-risk settings, the expected outbreak size increased and ORI response time had a greater impact on outcomes, with slower ORI response time scenarios having an increased proportion of simulations which exceeded 5000 cumulative cases.

ORI response time was more critical for absolute numbers of cases in higher risk setting archetypes, and the proportional impact of a faster ORI response time was also greater for outbreaks in these settings. Interestingly, the estimated impacts of faster response times decreased to 0% as the routine vaccine coverage approached 100% (Figure 4), which occurred because high routine vaccine coverage settings had smaller outbreaks and saw less benefit from fast ORI response times due to slower transmission. For example, in a setting with 50% routine vaccination coverage, a 15-day response time was estimated to avert ~55%

of the cases compared to the mean historical response time (120 days) between 2000-2022, while a 105-day response time averted ~13%. However, in a setting with 90% routine vaccine coverage, a 15-day response time was estimated to avert ~8% of the cases, while a 105-day response time averted no additional cases compared to a 120-day response time (Table S7 in Supplement 4).



Figure 4: Proportional reduction in the mean cumulative cases and deaths for the set of outbreaks with response times of 15, 30, 45, 60, 75, 90 and 105 days relative to the set of outbreaks with a response time of 120 days, estimated using bootstrap resampling. Proportional impacts are grouped vertically by routine vaccine coverage, and the values stated at the bottom of each column are the mean cumulative cases or deaths produced by outbreaks which received ORI after 120 days, i.e., the value serving as the denominator for the proportional reduction estimate.

Yellow fever

The expected size of the yellow fever outbreaks was strongly dependent on both the routine vaccine coverage (Figure S17, Figure S19 in Supplement 5) and the mosquito-human transmission modifier (Figure S18, Figure S20 in Supplement 5). The proportion of simulations exceeding certain high case thresholds decreased with routine coverage, increased with ORI response time (Figure 1 and Figure S21 in Supplement 5), and increased with the transmission modifier (Figure S22 in Supplement 5). When the routine vaccine coverage was high or the transmission modifier was low (i.e., in a low-risk setting archetype), outbreaks tended to be quite small even with longer response times. However, in a high-risk setting archetype, the expected outbreak size increased and slower response time scenarios increased the proportion of simulations which exceeded 500 or 1000 cumulative cases.

ORI response time was more critical for absolute numbers of cases in high-risk setting archetypes, and the proportional impact of a faster response time was also greater for outbreaks in these settings (Figure 5 and Figure S23 in Supplement 5). For example, when

the transmission modifier was fixed at 1·0, in a 50% routine vaccination setting, a 15-day response time was estimated to avert ~25% of the cases compared to the mean historical response time (105 days) between 2000-2022, while a 90-day response time averted no additional cases. While in an 80% coverage setting, a 15-day response time was estimated to avert ~11% of the cases, and a 90-day response time averted no additional cases compared to a 105-day response time (Tables S8, Table S9 in Supplement 5).



Figure 5: Proportional reduction in the mean cumulative cases and deaths for the set of outbreaks with response times of 15, 30, 45, 60, 75, and 90 days relative to the set of outbreaks with a response time of 105 days, estimated using bootstrap resampling and assuming a transmission modifier of 1·0 for the mosquito vectors. Proportional impacts are grouped vertically by routine vaccine coverage, and the values stated at the bottom of each column are the mean cumulative cases or deaths produced by outbreaks which received ORI after 105 days, i.e., the value serving as the denominator for the proportional reduction estimate.

Sensitivity analysis

The results of the alternate ORI coverage sensitivity analysis can be seen in Figures S24–40 in Supplement 6. For meningitis and cholera outbreaks, increasing achieved ORI coverage decreased the cumulative cases by up to 20–25%. For measles outbreaks, we found that when the achieved ORI coverage was low outbreaks grew quite large even with rapid ORI response times, because large proportions of the population were missed by the response. The effect varied by setting archetype, and we observed less impact from gains in ORI coverage achieved if the routine coverage level was higher.

The results of the daily vaccination rate sensitivity analysis can be seen in Figures S41–48 in Supplement 6. Meningitis, cholera, and measles outbreaks were insensitive to increasing the daily vaccination rate such that all doses are delivered in a single day because the Baseline assumptions are quite fast (varying by disease), but the yellow fever outbreaks were relatively sensitive to it and the total cases decreased by up to 40%. The impact of decreasing the

vaccination rate such that the doses are delivered over the course of a month varied by disease, and within each disease varied by response time or by setting archetype. The cholera, yellow fever, and measles ORI were sensitive to the decrease, particularly for faster ORI response times and settings with lower routine vaccine coverage (for measles). Yellow fever outbreaks in the highest risk setting archetypes were up to three times larger if the ORI took one month to vaccinate the population instead of one week, however such a slow rollout would be atypical.

Discussion

We used agent-based models to estimate the impact of faster ORI response times for outbreaks of measles, cholera, yellow fever, and meningococcal meningitis. We found that ORI responses initiated within the timeframe of the 7-1-7 framework (15 days of the outbreak beginning)[1] would avert a larger proportion of cases and deaths than the average response times for recent historical outbreaks in LMICs. In the model, a 15-day ORI response time reduced the expected burden of cases and deaths from meningococcal meningitis outbreaks by approximately 35%, cholera outbreaks by 80%, and from measles and yellow fever outbreaks in settings with low routine vaccine coverage by up to 55% and 35%, respectively. This is consistent with previous modelling analyses, which estimated that implementing vaccination responses faster for outbreaks of measles, Ebola, cholera, yellow fever, poliovirus, and meningococcal meningitis reduced disease burden[8, 16-23, 25, 26]. This also supports the push for frameworks like 7-1-7, because the diseases considered here are responsible for a large health burden in LMICs[28], and the time taken to initiate ORI is typically on the order of months[8, 11]. If ORI timeliness can be improved then delivering the same number of vaccines will have a much greater protective impact for the population at-risk.

Caution is needed when focusing on ambitious targets like 7-1-7, particularly when they are optimistic compared to current timeliness metrics for ORI in LMICs[3, 10], because it may be viewed as unrealistic to achieve in practice. A more nuanced approach, with incremental targets or a graded assessment of progress towards specified targets is preferable to an ‘all-or-nothing’ goal, and is more in-line with the intent of the 7-1-7 Alliance and Resolve to Save Lives to identify bottlenecks in outbreak response[1, 2, 29]. For example, consider a given year in which a country had no outbreak responses achieve 7-1-7, but 90% of its responses achieved 7-1-37 (for a total time of 45 days). If those responses were estimated to have averted a large proportion of disease burden relative to the country’s average response time from previous years, then the level of progress should be noted and a subsequent goal perhaps set towards 30 days, rather than being assessed as making no progress toward 7-1-7. Our results indicate that achieving a 15-day ORI response time could avert an additional 35–80% of cases and deaths, but we also examined the benefits of incrementally faster ORI response times, finding that any improvements relative to the average historical response times reduces both the expected outbreak size and negative health outcomes.

The benefits of incrementally improving ORI response times varied widely across diseases and setting archetypes, suggesting that there may be utility in having context-specific timeliness targets, and that efforts to improve ORI response times could be targeted for increased impact. When outbreaks were simulated in higher risk settings (i.e., those with lower routine vaccine coverage, higher initial prevalence, or higher transmission modifiers)

we consistently found a stronger relationship between ORI response time and outbreak size than in lower risk settings. By computing risk profiles for setting archetypes (as in Figure 1), context-dependent timeliness targets could be designed which minimise the risk of large outbreaks but are evidence-based and support prioritisation of limited resources for greatest benefit. For example, in a setting where the meningitis carriage prevalence in the lead-up to an epidemic season was suspected to be high (e.g., 10% in a district), a 30-day ORI response time may be adequate to keep the risk of an outbreak larger than 500 cases below 10%. For yellow fever, in low-risk outbreak settings, ORI response time may make minimal difference to outcomes and so efforts for improvement may be better directed elsewhere. This information allows decision makers to prioritise efforts where incremental improvements have the greatest impact.

Another factor to consider when designing ambitious targets for response time is the potential for diminishing returns. While it seems clear that a shorter response time would not lead to worse outcomes during an outbreak, our results indicate that it may not always produce better outcomes. In low-risk setting archetypes the impact of improving ORI response time on both outbreak size and proportional reductions was typically quite small, but the reasons for this are clear. High routine vaccine coverage reduces both the pool of susceptible people and the rate of transmission during an outbreak of measles or yellow fever, for example. What is more interesting is that there may be diminishing returns in high-risk settings as well, depending on the disease. For measles outbreaks in settings with low routine vaccine coverage there were benefits from each incremental improvement to ORI response time from the historical average of 120 days down to 60 days, with each 15-day improvement to this time reducing total cases by 10–15%, however for even faster responses there was almost no additional benefit. In contrast, for meningococcal meningitis, the expected size of an outbreak was modified by the initial carriage prevalence in the population before an epidemic season, but the proportional impact of each improvement in ORI response time was largely independent of this. We found that each 15-day improvement reduced the total cases by 7-10% for each choice of initial carriage.

This analysis focused on outbreaks of four vaccine preventable diseases — meningococcal meningitis, cholera, measles, and yellow fever — and found that the relationship between ORI response time and impact differs for all of them. However, there are some lessons that can be generalised across outbreaks of vaccine preventable diseases. Where there are known factors which affect outbreak risk or the rate of transmission, ORI response time is typically more critical in higher risk settings. As such, developing and maintaining systems of disease surveillance to assess these risks could help to inform the importance of rapid outbreak response. Strong surveillance systems would facilitate faster and more sensitive outbreak detection, a core tenet of 7-1-7, making rapid responses more achievable. Through development of technology and investments in health systems, the timeliness for both detection and response has improved over recent decades, but there is still room for growth[30, 31]. We believe there is potential for future mathematical modelling work to meaningfully inform the benefits of enhancements to surveillance systems on the impact of outbreak responses using models such as ours.

This was a broad modelling analysis, using four different agent-based models, and both the models and methodology are subject to limitations. Specific limitations for each disease model are described in Supplements 2–5. The study methodology was limited by the nature

of our calibration process, and by the assumptions which informed our scenarios. The calibration of our models was performed collectively on outbreak datasets of different sizes[8], and while each model reproduces the range of outbreak sizes observed in the data, they are biased towards the most frequently observed outbreak sizes. For the purposes of this prospective analysis, it means that the model simulations represented outbreaks similar to the average outbreak observed between 2000–2023 for each disease, but future outbreaks may behave differently. We aimed to understand the effects of the key parameter assumptions in our scenarios by showing simulations over a range of setting archetypes, and by performing a sensitivity analysis for the daily vaccination rate and achieved ORI coverage, but outbreaks and responses which exist outside of the considered range of the parameters may not be well represented by our results. Finally, our analysis only considered the impact of improvements to ORI timeliness, and no other components of outbreak response, noting ORI is only one aspect amongst the seven key early response actions within the 7-day response component of the 7-1-7 metric. We also did not disaggregate the ORI response times by detection-notification-response as defined by 7-1-7. As such we do not capture impacts from faster implementation of programs such as contact tracing, or distinguish whether timeliness improvements were made for detection, notification, or response.

Conclusion

The results of this analysis indicate that achieving a 15-day vaccine response to outbreaks of measles, cholera, yellow fever, or meningococcal meningitis in LMICs, as per the 7-1-7 targets, could prevent a large disease burden. Furthermore, we found that there are benefits to be gained from incremental improvements to response time even when 7-1-7 is not achieved, and we support focusing on incremental improvements in timeliness irrespective of whether the 7-1-7 target is routinely achievable. We found a risk-associated variability in the impact of achieving faster responses, where response time gains were more impactful in higher risk settings than lower risk settings. Therefore, we expect that a graded approach paired with context-specific risk assessments could also facilitate resource prioritisation decisions if multiple outbreaks occur in a short timeframe.

Author contributions

Conceptualization, D.D., R.G.A. and N.S.; formal analysis, D.D.; investigation (data gathering), D.D.; investigation (modelling), D.D.; methodology, D.D., R.G.A. and N.S.; project administration, N.S.; software, D.D., A.M.M. and R.G.A.; supervision, R.G.A. and N.S.; validation, D.D., A.M.M., J.G., R.G.A. and N.S.; visualization, D.D.; writing—original draft, D.D.; writing—review and editing, D.D., A.M.M., J.G., R.G.A. and N.S.

Conflicts of interest

D.D. has received funding for a PhD scholarship from the National Health and Medical Research Council in Australia. No author has been paid to write this article by a pharmaceutical company or other agency. Authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.

Data sharing

Model code and outbreak data used during model calibration will be published on Zenodo alongside the publication of this manuscript and will be publicly available indefinitely.

References

1. Frieden TR, Lee CT, Bochner AF, Buissonniere M, McClelland A. 7-1-7: an organising principle, target, and accountability metric to make the world safer from pandemics. Lancet. 2021;398(10300):638-40.
2. Bochner AF, Makumbi I, Aderinola O, Abayneh A, Jetoh R, Yemanaberhan RL, et al. Implementation of the 7-1-7 target for detection, notification, and response to public health threats in five countries: a retrospective, observational study. Lancet Glob Health. 2023;11(6):e871-e9.
3. Impouma B, Roelens M, Williams GS, Flahault A, Codeco CT, Moussana F, et al. Measuring Timeliness of Outbreak Response in the World Health Organization African Region, 2017-2019. Emerg Infect Dis. 2020;26(11):2555-64.
4. Disease Outbreak News: annual compendium 2022. Geneva: World Health Organization; 2023.
5. Realizing Africa CDC's Autonomy: Making Measurable Impact in Africa's Health Security. Addis Ababa, Ethiopia: Africa Centres for Disease Control and Prevention; 2024.
6. Carter A, Msemburi W, Sim SY, Gaythorpe KAM, Lambach P, Lindstrand A, et al. Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030. Vaccine. 2024;42 Suppl 1:S28-S37.
7. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet. 2024;403(10441):2307-16.
8. Delport D, Muellenmeister AM, MacKechnie G, Vaccher S, Mengistu T, Hogan D, et al. Estimating the historical impact of outbreak response immunization programs across 210 outbreaks in LMICs. 2024:2024.06.02.24308241.
9. International Coordinating Group (ICG) on Vaccine Provision - About us: World Health Organization; [Accessed 2025-01-06]. Available from: https://www.who.int/groups/icg.
10. Fieldhouse JK, Randhawa N, Fair E, Bird B, Smith W, Mazet JAK. One Health timeliness metrics to track and evaluate outbreak response reporting: A scoping review. EClinicalMedicine. 2022;53:101620.
11. Pezzoli L. Global oral cholera vaccine use, 2013–2018. Vaccine. 2020;38:A132-A40.
12. Crawley AW, Divi N, Smolinski MS. Using Timeliness Metrics to Track Progress and Identify Gaps in Disease Surveillance. Health Secur. 2021;19(3):309-17.
13. Smolinski MS, Crawley AW, Olsen JM. Finding Outbreaks Faster. Health Secur. 2017;15(2):215-20.
14. Fieldhouse J, Nakiire L, Kayiwa J, Brindis CD, Mitchell A, Makumbi I, et al. How feasible or useful are timeliness metrics as a tool to optimise One Health outbreak responses? BMJ Glob Health. 2024;9(7).
15. Immunization Agenda 2030 Scorecard SP5.1: Outbreak Detection and Response [Accessed 2024-11-25]. Available from: https://scorecard.immunizationagenda2030.org/sp5.1.
16. Grais RF, Conlan AJ, Ferrari MJ, Djibo A, Le Menach A, Bjornstad ON, et al. Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J R Soc Interface. 2008;5(18):67-74.

17. Yagci Sokat K, Armbruster B. Modeling and Controlling Epidemic Outbreaks: The Role of Population Size, Model Heterogeneity and Fast Response in the Case of Measles. 2020;8(11):1892.
18. Kellerborg K, Brouwer W, van Baal P. Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. Cost Eff Resour Alloc. 2020;18:13.
19. Trotter CL, Cibrelus L, Fernandez K, Lingani C, Ronveaux O, Stuart JM. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac(R). Vaccine. 2015;33(46):6212-7.
20. Cooper LV, Ronveaux O, Fernandez K, Lingani C, Goumbi K, Ihekweazu C, et al. Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response. J Infect Dis. 2019;220(220 Suppl 4):S244-S52.
21. Ferrari MJ, Fermon F, Nackers F, Llosa A, Magone C, Grais RF. Time is (still) of the essence: quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria. Int Health. 2014;6(4):282-90.
22. Zhao S, Stone L, Gao D, He D. Modelling the large-scale yellow fever outbreak in Luanda, Angola, and the impact of vaccination. PLoS Negl Trop Dis. 2018;12(1):e0006158.
23. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. 2023;41 Suppl 1(Suppl 1):A136-A41.
24. Laydon DJ, Cauchemez S, Hinsley WR, Bhatt S, Ferguson NM. Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study. Lancet Glob Health. 2023;11(5):e759-e69.
25. Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, Lopez AL, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011;5(1):e952.
26. Azam JM, Saitta B, Bonner K, Ferrari MJ, Pulliam JRC. Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response. Vaccine. 2021;39(40):5845-53.
27. Starsim github repository.
28. Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2133-61.
29. 7-1-7 Digital Toolkit: 7-1-7 Alliance; [Accessed 2025-01-06]. Available from: https://717alliance.org/digital-toolkit/.
30. Houlihan CF, Whitworth JA. Outbreak science: recent progress in the detection and response to outbreaks of infectious diseases. Clin Med (Lond). 2019;19(2):140-4.
31. Kluberg SA, Mekaru SR, McIver DJ, Madoff LC, Crawley AW, Smolinski MS, et al. Global Capacity for Emerging Infectious Disease Detection, 1996-2014. Emerg Infect Dis. 2016;22(10):E1-6.